Gemma Casadesus

List of Publications by Year
in descending order

97 papers	8,209 citations	50566 48 h-index	53065 89 g-index
98 all docs	98 docs citations	98 times ranked	12159 citing authors

#	Article	IF	Citations
1	The Importance of Understanding Amylin Signaling Mechanisms for Therapeutic Development in the Treatment of Alzheimerâ€™s Disease. Current Pharmaceutical Design, 2020, 26, 1345-1355.	0.9	3
2	Automated Isoform Diversity Detector (AIDD): a pipeline for investigating transcriptome diversity of RNA-seq data. BMC Bioinformatics, 2020, 21, 578.	1.2	3
3	The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimerâ€™s Dementia. Frontiers in Aging Neuroscience, 2019, 11, 236.	1.7	40
4	Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimerâ€™s Disease Are Associated with Oxidative Stress Regulation Mechanisms. Journal of Alzheimer's Disease, 2019, 69, 157-168.	1.2	15
5	CNS luteinizing hormone receptor activation rescues ovariectomy-related loss of spatial memory and neuronal plasticity. Neurobiology of Aging, 2019, 78, 111-120.	1.5	15
6	c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments. Journal of Molecular Medicine, 2019, 97, 1723-1733.	1.7	10
7	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 7327-7339.	1.9	24
8	Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. Journal of Alzheimer's Disease, 2018, 62, 1223-1240.	1.2	150
9	Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 4885-4895.	1.9	21
10	Neuroprotective Effects of Amylin Analogues on Alzheimerâ€™s Disease Pathogenesis and Cognition. Journal of Alzheimer's Disease, 2018, 66, 11-23.	1.2	15
11	Luteinizing Hormone Involvement in Aging Female Cognition: Not All Is Estrogen Loss. Frontiers in Endocrinology, 2018, 9, 544.	1.5	25
12	Experimental Models for Aging and their Potential for Novel Drug Discovery. Current Neuropharmacology, 2018, 16, 1466-1483.	1.4	35
13	Individual Case Analysis of Postmortem Interval Time on Brain Tissue Preservation. PLoS ONE, 2016, 11, e0151615.	1.1	81
14	The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease. Nutrition Research, 2016, 36, 1305-1315.	1.3	17
15	Luteinizing hormone downregulation but not estrogen replacement improves ovariectomy-associated cognition and spine density loss independently of treatment onset timing. Hormones and Behavior, 2016, 78, 60-66.	1.0	26
16	HypothalamicÃ¢â‚¬â€œPituitaryÃ¢â‚¬â€œGonadal Axis Involvement in Learning and Memory and AlzheimerÃ¢â‚¬â„¢s Disease: More than Ã¢â‚¬Å“JustÃ¢â‚¬Â•Estrogen. Frontiers in Endocrinology, 2015, 6, 45.	1.5	38
17	From Neurodegeneration to Brain Health: AnÂIntegrated Approach. Journal of Alzheimer's Disease, 2015, 46, 271-283.	1.2	6
18	Luteinizing hormone: Evidence for direct action in the CNS. Hormones and Behavior, 2015, 76, 57-62.	1.0	42

#	Article	IF	Citations
19	Fatty Acid-binding Protein 5 (FABP5) Regulates Cognitive Function Both by Decreasing Anandamide Levels and by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor Î²/Î´ (PPARÎ²/Î´) in the Brain. Journal of Biological Chemistry, 2014, 289, 12748-12758.	1.6	74
20	Downâ€regulation of serum gonadotropins but not estrogen replacement improves cognition in agedâ€ovariectomized 3xTg <scp>AD</scp> female mice. Journal of Neurochemistry, 2014, 130, 115-125.	2.1	44
21	Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. Journal of Neurochemistry, 2014, 128, 162-172.	2.1	110
22	Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiology of Aging, 2014, 35, 793-801.	1.5	114
23	Accumulation of Intraneuronal Amyloid-β is Common in Normal Brain. Current Alzheimer Research, 2014, 11, 317-324.	0.7	16
24	Respiratory and behavioral dysfunction following loss of the <scp>GABA</scp>_A receptor Î±4 subunit. Brain and Behavior, 2013, 3, 104-113.	1.0	12
25	Mitochondrial Abnormalities in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 406-419.	0.7	106
26	LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Human Molecular Genetics, 2012, 21, 1931-1944.	1.4	356
27	Neuronal Cell Cycle Re-Entry Markers are Altered in the Senescence Accelerated Mouse P8 (SAMP8). Journal of Alzheimer's Disease, 2012, 30, 573-583.	1.2	27
28	LRRK2 Directly Interacts with DLP1 to Regulate Mitochondrial Dynamics and Function. Microscopy and Microanalysis, 2012, 18, 196-197.	0.2	0
29	Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiology of Aging, 2012, 33, 2062-2071.	1.5	195
30	Klf15 Orchestrates Circadian Nitrogen Homeostasis. Cell Metabolism, 2012, 15, 311-323.	7.2	119
31	Activation of the extracellular signalâ€regulated kinase pathway contributes to the behavioral deficit of fragile xâ€syndrome. Journal of Neurochemistry, 2012, 121, 672-679.	2.1	78
32	Neuroendocrinologyâ€based therapy for Alzheimer's disease. BioFactors, 2012, 38, 123-132.	2.6	5
33	Retinoids for treatment of Alzheimer's disease. BioFactors, 2012, 38, 84-89.	2.6	36
34	Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimerâ€™s disease. Journal of Neurochemistry, 2012, 120, 419-429.	2.1	422
35	Frontiers in Alzheimerâ€™s disease therapeutics. Therapeutic Advances in Chronic Disease, 2011, 2, 9-23.	1.1	26
36	Transection of CA3 does not affect memory performance in rats. Epilepsy and Behavior, 2011, 21, 267-270.	0.9	6

#	Article	IF	Citations
37	The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurology, The, 2011, 10, 275-279.	4.9	197
38	Antioxidant approaches for the treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 1201-1208.	1.4	103
39	Downâ€regulation of serum gonadotropins is as effective as estrogen replacement at improving menopauseâ€associated cognitive deficits. Journal of Neurochemistry, 2010, 112, 870-881.	2.1	53
40	Mitochondrial biology in Alzheimerâ€™s disease pathogenesis. Journal of Neurochemistry, 2010, 114, 933-945.	2.1	66
41	Review: Cell cycle aberrations and neurodegeneration. Neuropathology and Applied Neurobiology, 2010, 36, 157-163.	1.8	65
42	Pet-1 is required across different stages of life to regulate serotonergic function. Nature Neuroscience, 2010, 13, 1190-1198.	7.1	155
43	Early Amyloid Accumulation in the Hippocampus of SAMP8 Mice. Journal of Alzheimer's Disease, 2010, 19, 1303-1315.	1.2	119
44	Leptin Reduces Pathology and Improves Memory in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 1155-1167.	1.2	195
45	Memantine. American Journal of Pathology, 2010, 176, 540-541.	1.9	4
46	Autophagy in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 1209-1218.	1.4	51
47	Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection. Current Neurovascular Research, 2009, 6, 70-81.	0.4	151
48	Activation of Akt by lithium: Pro-survival pathways in aging. Mechanisms of Ageing and Development, 2009, 130, 253-261.	2.2	43
49	The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Research, 2009, 1249, 244-250.	1.1	37
50	A novel approach to the identification and quantitative elemental analysis of amyloid depositsâ€”Insights into the pathology of Alzheimerâ€™s disease. Biochemical and Biophysical Research Communications, 2009, 382, 91-95.	1.0	96
51	Neuroprotection by c-Jun NH2-terminal kinase inhibitor SP600125 against potassium deprivationâ€“induced apoptosis involves the Akt pathway and inhibition of cell cycle reentry. Neuroscience, 2009, 159, 1135-1147.	1.1	30
52	The X-chromosome instability phenotype in Alzheimerâ€™s disease: A clinical sign of accelerating aging?. Medical Hypotheses, 2009, 73, 917-920.	0.8	24
53	Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochemistry International, 2009, 54, 84-88.	1.9	125
54	Leptin inhibits glycogen synthase kinase-3Î² to prevent tau phosphorylation in neuronal cells. Neuroscience Letters, 2009, 455, 191-194.	1.0	110

#	Article	IF	Citations
55	Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radical Research, 2009, 43, 156-164.	1.5	65
56	All-transretinoic acid as a novel therapeutic strategy for Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2009, 9, 1615-1621.	1.4	104
57	Cell cycle aberrations in Alzheimerâ€™s disease: a novel therapeutic opportunity. Expert Review of Neurotherapeutics, 2009, 9, 1579-1580.	1.4	6
58	Leptin: A Novel Therapeutic Strategy for Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 731-740.	1.2	114
59	The Neuronal Expression of MYC Causes a Neurodegenerative Phenotype in a Novel Transgenic Mouse. American Journal of Pathology, 2009, 174, 891-897.	1.9	82
60	Clinical benefit and preservation of flavonols in dark chocolate manufacturing. Nutrition Reviews, 2008, 66, 630-641.	2.6	64
61	Neuroprotective effects of SBâ€415286 on hydrogen peroxideâ€induced cell death in B65 rat neuroblastoma cells and neurons. International Journal of Developmental Neuroscience, 2008, 26, 269-276.	0.7	19
62	Leptin reduces Alzheimerâ€™s disease-related tau phosphorylation in neuronal cells. Biochemical and Biophysical Research Communications, 2008, 376, 536-541.	1.0	116
63	Amyloid-Î² overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19318-19323.	3.3	734
64	Lithium Treatment Decreases Activities of Tau Kinases in a Murine Model of Senescence. Journal of Neuropathology and Experimental Neurology, 2008, 67, 612-623.	0.9	49
65	Menopause, Estrogen, and Gonadotropins in Alzheimer's Disease. Advances in Clinical Chemistry, 2008, 45, 139-153.	1.8	10
66	From Aging to Alzheimer's Disease: Unveiling â€œThe Switchâ€•with the Senescence-Accelerated Mouse Model (SAMP8). Journal of Alzheimer's Disease, 2008, 15, 615-624.	1.2	177
67	Overexpression of the Cytosolic Form of Phosphoenolpyruvate Carboxykinase (GTP) in Skeletal Muscle Repatterns Energy Metabolism in the Mouse. Journal of Biological Chemistry, 2007, 282, 32844-32855.	1.6	169
68	The Contribution of Luteinizing Hormone to Alzheimer Disease Pathogenesis. Clinical Medicine and Research, 2007, 5, 177-183.	0.4	39
69	Signal Transduction Cascades Associated with Oxidative Stress in Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 11, 143-152.	1.2	95
70	Increases in luteinizing hormone are associated with declines in cognitive performance. Molecular and Cellular Endocrinology, 2007, 269, 107-111.	1.6	103
71	Vascular oxidative stress in Alzheimer disease. Journal of the Neurological Sciences, 2007, 257, 240-246.	0.3	164
72	Neuroprotective effects of caffeine against complex I inhibitionâ€“induced apoptosis are mediated by inhibition of the Atm/p53/E2Fâ€1 path in cerebellar granule neurons. Journal of Neuroscience Research, 2007, 85, 3079-3088.	1.3	33

#	Article	IF	Citations
73	Exposure to 56Fe irradiation accelerates normal brain aging and produces deficits in spatial learning and memory. Advances in Space Research, 2007, 39, 1087-1092.	1.2	23
74	Increased permeability of bloodâ€“brain barrier on the hippocampus of a murine model of senescence. Mechanisms of Ageing and Development, 2007, 128, 522-528.	2.2	82
75	Indices of Metabolic Dysfunction and Oxidative Stress. Neurochemical Research, 2007, 32, 717-722.	1.6	23
76	The Estrogen Myth. Drugs in R and D, 2006, 7, 187-193.	1.1	25
77	Neurogenesis in Human Hippocampus: Implications for Alzheimer Disease Pathogenesis. Neuroembryology and Aging, 2006, 4, 175-182.	0.1	4
78	Synaptic dysfunction and oxidative stress in Alzheimer's disease: Emerging mechanisms. Journal of Cellular and Molecular Medicine, 2006, 10, 796-805.	1.6	78
79	The Cell Cycle and Hormonal Fluxes in Alzheimer Disease: A Novel Therapeutic Target. Current Pharmaceutical Design, 2006, 12, 691-697.	0.9	20
80	Estrogen Bows to a New Master: The Role of Gonadotropins in Alzheimer Pathogenesis. Annals of the New York Academy of Sciences, 2005, 1052, 201-209.	1.8	43
81	Oxidative Imbalance in Alzheimer's Disease. Molecular Neurobiology, 2005, 31, 205-218.	1.9	126
82	Hippocampal neurogenesis and PSA-NCAM expression following exposure to Fe particles mimics that seen during aging in rats. Experimental Gerontology, 2005, 40, 249-254.	1.2	39
83	The cell cycle in Alzheimer disease: A unique target for neuropharmacology. Mechanisms of Ageing and Development, 2005, 126, 1019-1025.	2.2	97
84	Oxidative Stress and Inflammation in Brain Aging: Nutritional Considerations. Neurochemical Research, 2005, 30, 927-935.	1.6	121
85	Therapeutic Opportunities in Alzheimer Disease: One for all or all for One?. Current Medicinal Chemistry, 2005, 12, 1137-1147.	1.2	49
86	Modulation of Hippocampal Plasticity and Cognitive Behavior by Short-term Blueberry Supplementation in Aged Rats. Nutritional Neuroscience, 2004, 7, 309-316.	1.5	272
87	Oxidative Stress and Redox-Active Iron in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2004, 1012, 179-182.	1.8	179
88	The effects of heavy particle irradiation on exploration and response to environmental change. Advances in Space Research, 2004, 33, 1340-1346.	1.2	29
89	Oxidative stress signalling in Alzheimer's disease. Brain Research, 2004, 1000, 32-39.	1.1	377
90	Alzheimer disease: Evidence for a central pathogenic role of iron-mediated reactive oxygen species. Journal of Alzheimer's Disease, 2004, 6, 165-169.	1.2	100

#	Article	IF	Citations
91	Perspectives on the Amyloid-Î² Cascade Hypothesis. Journal of Alzheimer's Disease, 2004, 6, 137-145.	1.2	56
92	Mitotic and Gender Parallels in Alzheimer Disease: Therapeutic Opportunities. Current Drug Targets, 2004, 5, 559-563.	1.0	6
93	A metabolic basis for Alzheimer disease. Neurochemical Research, 2003, 28, 1549-1552.	1.6	51
94	Cognitive deficits induced by 56Fe radiation exposure. Advances in Space Research, 2003, 31, 119-126.	1.2	68
95	Qualitative versus quantitative caloric intake: are they equivalent paths to successful aging?. Neurobiology of Aging, 2002, 23, 747-769.	1.5	34
96	Amyloid-Î² and Ï„ serve antioxidant functions in the aging and Alzheimer brain. Free Radical Biology and Medicine, 2002, 33, 1194-1199.	1.3	194
97	Automated measurement of age-related changes in the locomotor response to environmental novelty and home-cage activity. Mechanisms of Ageing and Development, 2001, 122, 1887-1897.	2.2	29